Moderna (MRNA) has maxed out on its manufacturing capacity for 2021 and has shifted its focus to 2022 and 2023 advanced purchasing orders for its COVID-19 vaccine, officials said Thursday.
The company reported $2.8 billion in vaccine revenue for the second quarter and anticipates pricing of doses will fall and impact revenue as more low- and middle-income countries become the dominant purchasers, according to officials on an earnings call.
In addition, Moderna expects the global pandemic to…
Source link
